Dossier assessment
Brivaracetam (epilepsy in children [aged 2 to < 4 years]) - Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Brivaracetam (epilepsy in children [aged 2 to < 4 years]) - Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Brivaracetam (epilepsy in children [aged 2 to < 4 years]) - Benefit assessment according to §35a Social Code Book V
Dossier assessment
Adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalization in children from ≥ 2 to < 4 years of age with epilepsy
Added benefit not proven
Project details
- Project no.
- A22-32
- Commission
- Commission awarded on 28.02.2022 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Children's and adolescents' health
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
Connected Projects
-
Dossier assessment
Brivaracetam (epilepsy) - Benefit assessment in accordance with §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Brivaracetam - Benefit assessment according to §35a Social Code Book V
Status: Commission completed